<DOC>
	<DOC>NCT01521884</DOC>
	<brief_summary>People affected by rheumatoid arthritis are often suffering from fatigue and decreased QOL. In this study we are measuring the impact of SC biologics on these parameters.</brief_summary>
	<brief_title>Study Looking at Longitudinal Changes in Fatigue and Health Status in Rheumatoid Arthritis (RA) Patients Treated With Subcutaneous Anti-TNF-α Therapy</brief_title>
	<detailed_description>Observational prospective study Purely descriptive</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<criteria>Patients who: Are active RA patients (as judged by treating MD) Are 18 years of age or older at time of consent Are scheduled by their rheumatologist to initiate SC antiTNFα therapy + MTX Use of biologics (or any experimental drug) in the last 3 months before initiation of SC antiTNFα therapy. Participation in other clinical or observational trials</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>